X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare GSK Pharma with Aurobindo Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

GSK PHARMA vs AUROBINDO PHARMA - Comparison Results

GSK PHARMA    Change

GSK Pharma is one of the leading MNC pharma companies in the Indian market. It is a 50.7% subsidiary of GlaxoSmithKline Plc, one of the world's largest pharma companies. GSK Pharma's product portfolio boasts of some of the leading brands like Augment... More

AUROBINDO PHARMA 
   Change

Aurobindo Pharma is one of India's top 5 pharma companies in terms of turnover, and has presence in the generic and Active Pharmaceutical Ingredients (API) segments. The company's robust product portfolio is spread across 6 product areas, including a... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    GSK PHARMA AUROBINDO PHARMA GSK PHARMA/
AUROBINDO PHARMA
 
P/E (TTM) x 53.8 19.8 271.7% View Chart
P/BV x 10.7 3.9 273.0% View Chart
Dividend Yield % 2.7 0.3 842.8%  

Financials

 GSK PHARMA   AUROBINDO PHARMA
EQUITY SHARE DATA
    GSK PHARMA
Mar-18
AUROBINDO PHARMA
Mar-18
GSK PHARMA/
AUROBINDO PHARMA
5-Yr Chart
Click to enlarge
High Rs2,760809 341.2%   
Low Rs2,040504 404.8%   
Sales per share (Unadj.) Rs339.0281.1 120.6%  
Earnings per share (Unadj.) Rs41.441.4 100.1%  
Cash flow per share (Unadj.) Rs45.950.9 90.2%  
Dividends per share (Unadj.) Rs35.002.50 1,400.0%  
Dividend yield (eoy) %1.50.4 383.0%  
Book value per share (Unadj.) Rs242.9199.4 121.8%  
Shares outstanding (eoy) m84.70585.88 14.5%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x7.12.3 303.1%   
Avg P/E ratio x57.915.9 365.0%  
P/CF ratio (eoy) x52.312.9 405.2%  
Price / Book Value ratio x9.93.3 300.1%  
Dividend payout %84.56.0 1,397.9%   
Avg Mkt Cap Rs m203,280384,630 52.9%   
No. of employees `000NA17.3 0.0%   
Total wages/salary Rs m5,23421,308 24.6%   
Avg. sales/employee Rs ThNM9,500.7-  
Avg. wages/employee Rs ThNM1,229.4-  
Avg. net profit/employee Rs ThNM1,397.9-  
INCOME DATA
Net Sales Rs m28,715164,666 17.4%  
Other income Rs m5451,020 53.5%   
Total revenues Rs m29,260165,686 17.7%   
Gross profit Rs m5,05937,718 13.4%  
Depreciation Rs m3805,580 6.8%   
Interest Rs m2777 0.3%   
Profit before tax Rs m5,22232,380 16.1%   
Minority Interest Rs m031 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m1780-   
Tax Rs m1,8928,183 23.1%   
Profit after tax Rs m3,50824,229 14.5%  
Gross profit margin %17.622.9 76.9%  
Effective tax rate %36.225.3 143.4%   
Net profit margin %12.214.7 83.0%  
BALANCE SHEET DATA
Current assets Rs m21,815121,878 17.9%   
Current liabilities Rs m15,99986,806 18.4%   
Net working cap to sales %20.321.3 95.1%  
Current ratio x1.41.4 97.1%  
Inventory Days Days64130 49.0%  
Debtors Days Days1968 27.3%  
Net fixed assets Rs m12,47581,037 15.4%   
Share capital Rs m847586 144.6%   
"Free" reserves Rs m19,726116,218 17.0%   
Net worth Rs m20,573116,804 17.6%   
Long term debt Rs m64,512 0.1%   
Total assets Rs m39,475211,052 18.7%  
Interest coverage x2,612.042.7 6,122.4%   
Debt to equity ratio x00 0.8%  
Sales to assets ratio x0.70.8 93.2%   
Return on assets %8.911.8 75.0%  
Return on equity %17.120.7 82.2%  
Return on capital %26.227.4 96.0%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m56480,727 0.7%   
Fx outflow Rs m7,42934,700 21.4%   
Net fx Rs m-6,86546,027 -14.9%   
CASH FLOW
From Operations Rs m4,72819,548 24.2%  
From Investments Rs m-1,042-19,570 5.3%  
From Financial Activity Rs m-3,0668,642 -35.5%  
Net Cashflow Rs m6208,922 6.9%  

Share Holding

Indian Promoters % 0.0 54.1 -  
Foreign collaborators % 50.7 0.0 -  
Indian inst/Mut Fund % 10.2 8.0 128.3%  
FIIs % 23.8 27.7 85.9%  
ADR/GDR % 0.0 0.0 -  
Free float % 15.4 10.2 151.0%  
Shareholders   102,036 69,601 146.6%  
Pledged promoter(s) holding % 0.0 8.6 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare GSK PHARMA With:   TTK HEALTHCARE  ALEMBIC LTD  CIPLA  ELDER PHARMA  SUVEN LIFESCIENCES  

Compare GSK PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends Marginally Lower; Banking and Automobile Stocks Witness Selling(Closing)

After opening the day on a strong note, Indian share markets witnessed selling pressure during closing hours and ended their trading session marginally lower.

Related Views on News

AUROBINDO PHARMA Announces Quarterly Results (3QFY19); Net Profit Up 19.3% (Quarterly Result Update)

Feb 12, 2019 | Updated on Feb 12, 2019

For the quarter ended December 2018, AUROBINDO PHARMA has posted a net profit of Rs 7 bn (up 19.3% YoY). Sales on the other hand came in at Rs 53 bn (up 21.5% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

GSK PHARMA Announces Quarterly Results (3QFY19); Net Profit Up 26.0% (Quarterly Result Update)

Feb 5, 2019 | Updated on Feb 5, 2019

For the quarter ended December 2018, GSK PHARMA has posted a net profit of Rs 1 bn (up 26.0% YoY). Sales on the other hand came in at Rs 8 bn (up 17.3% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.

AUROBINDO PHARMA 2017-18 Annual Report Analysis (Annual Result Update)

Dec 19, 2018 | Updated on Dec 19, 2018

Here's an analysis of the annual report of AUROBINDO PHARMA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of AUROBINDO PHARMA. Also includes updates on the valuation of AUROBINDO PHARMA.

AUROBINDO PHARMA Announces Quarterly Results (2QFY19); Net Profit Down 21.6% (Quarterly Result Update)

Nov 14, 2018 | Updated on Nov 14, 2018

For the quarter ended September 2018, AUROBINDO PHARMA has posted a net profit of Rs 6 bn (down 21.6% YoY). Sales on the other hand came in at Rs 48 bn (up 7.1% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

GSK PHARMA Announces Quarterly Results (2QFY19); Net Profit Down 22.7% (Quarterly Result Update)

Oct 23, 2018 | Updated on Oct 23, 2018

For the quarter ended September 2018, GSK PHARMA has posted a net profit of Rs 1 bn (down 22.7% YoY). Sales on the other hand came in at Rs 8 bn (down 2.4% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.

More Views on News

Most Popular

3 Indian Stocks with Amazon-Like Potential(Profit Hunter)

Apr 10, 2019

We have identified 3 stocks with huge wealth building potential which meet our 'Click of a Button' criteria.

This Company is Making a Big Comeback and You Can Now Profit from Its Example(The 5 Minute Wrapup)

Apr 10, 2019

How Dell got its mojo back.

This is Why the Stock of Jubilant FoodWorks Went Up 1,160%(The 5 Minute Wrapup)

Apr 12, 2019

This critical business strategy has enabled companies to scale their operations faster.

Pocketing Massive Gains with HDFC And HDFC Bank(Profit Hunter)

Apr 12, 2019

Here's how one could have generated gains of Rs 59,250 in 10 days by trading HDFC and HDFC Bank with a capital of Rs 4 lakh.

A Simple 3-Point Investing Manifesto for You the Indian Investor(The 5 Minute Wrapup)

Apr 11, 2019

A must have checklist for every investor in the Indian stock market.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

GSK PHARMA SHARE PRICE


Apr 23, 2019 03:35 PM

TRACK GSK PHARMA

  • Track your investment in GSK PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

GSK PHARMA - ASTRAZENECA PHARMA COMPARISON

COMPARE GSK PHARMA WITH

MARKET STATS